Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

Area of Science:

• Oncology
• Pharmacology
• Clinical Medicine

Background:

• Significant expansion in drug development for human epidermal growth factor receptor-2 (HER-2) positive breast cancer over the past 15 years.
• Current FDA-approved therapies include trastuzumab, pertuzumab, ado-trastuzumab emtansine, and lapatinib for HER-2 over-expressed breast cancer.

Purpose of the Study:

• To provide a succinct, updated review of the state-of-the-art management of HER-2 positive breast cancer.
• To critically appraise existing literature and highlight key clinical concepts for practical application.
• To identify promising future therapeutic strategies currently under investigation.

Main Methods:

• Comprehensive literature review of clinical research and drug development in HER-2 positive breast cancer.
• Synthesis of information across adjuvant, neoadjuvant, and metastatic clinical scenarios.
• Critical analysis of clinical trial data and treatment guidelines.

Main Results:

• Summary of established and emerging treatment options for HER-2 positive breast cancer.
• Identification of critical clinical considerations in managing HER-2 positive disease.
• Overview of novel therapeutic agents and strategies in clinical development.

Conclusions:

• Periodic reviews are essential to integrate the wealth of clinical research into daily practice for HER-2 positive breast cancer.
• A critical appraisal of current knowledge and future directions is crucial for optimizing patient outcomes.
• Emerging therapies hold promise for further improving treatment efficacy in all stages of HER-2 positive breast cancer.